NCT07218783View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2031

Conditions
CataractGlaucomaOcular Hypertension
Interventions
DRUG

Bimatoprost Implant System

Bimatoprost Implant System used in combination with the SpyGlass IOL

DEVICE

SpyGlass IOL

SpyGlass Intraocular Lens

DRUG

Timolol Maleate Ophthalmic Solution, 0.5%

Timolol Maleate Ophthalmic Solution, 0.5% BID

DEVICE

Commercial IOL

Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

Trial Locations (1)

77025

RECRUITING

Houston Eye Associates, Houston

All Listed Sponsors
lead

SpyGlass Pharma, Inc.

INDUSTRY

NCT07218783 - Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) | Biotech Hunter | Biotech Hunter